Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 47.04% is 28% below its 5-year average of 65.02%, near the low end of its 5-year range (3.51%–2764.05%).
As of the fiscal period ended Tuesday, June 30, 2026. 15.07% below its 12-month average of 55.38%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 47.04%.
DEBT TO ASSETS RATIO
47.04%
DEBT TO ASSETS RATIO AVG TTM
55.38%
DEBT TO ASSETS RATIO AVG 3Y
748.46%
DEBT TO ASSETS RATIO AVG 5Y
65.02%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-15.07%
CURRENT VS 3Y AVG
-93.72%
CURRENT VS 5Y AVG
-27.66%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 597 covered companies
CURRENT VS SECTOR MEDIAN
+46935.87%
vs the sector median at left
Jupiter Neurosciences, Inc.
Market Cap
$1.15M
Debt to Assets Ratio
47.04%
TTM Avg
55.38%
3Y Avg
748.46%
5Y Avg
65.02%
Market Cap
$1.10M
Debt to Assets Ratio
0.10%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.05M
Debt to Assets Ratio
0.11%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.01M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.38M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$893920.00
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Jupiter Neurosciences, Inc. (JUNS) | $1.15M | 47.04% | 55.38% | 748.46% | 65.02% |
| IM Cannabis Corp. (IMCC)vs › | $1.18M | 0.56% | N/A | N/A | N/A |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.10M | 0.10% | N/A | N/A | N/A |
| Clearmind Medicine Inc. (CMND)vs › | $1.05M | 0.11% | N/A | N/A | N/A |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.01M | 0.00% | N/A | N/A | N/A |
| Genprex, Inc. (GNPX)vs › | $1.31M | 0.00% | N/A | N/A | N/A |
| NewcelX Ltd. (NCEL)vs › | $1.35M | 0.04% | N/A | N/A | N/A |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.38M | 0.01% | N/A | N/A | N/A |
| GlucoTrack, Inc. (GCTK)vs › | $893920.00 | 0.01% | N/A | N/A | N/A |
| Bone Biologics Corporation (BBLG)vs › | $874595.00 | 0.00% | N/A | N/A | N/A |
Debt/Assets
47.0%
Debt/Equity
N/A
Current Ratio
0.66
Interest Coverage
-134.9x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 47.04% |
| 2026-03-31 | 122.40% |
| 2025-12-31 | 95.60% |
| 2025-09-30 | 7.00% |
| 2025-06-30 | 4.86% |
| 2025-03-31 | 4.14% |
| 2024-12-31 | 3.51% |
| 2024-09-30 | 2764.05% |
| 2024-06-30 | 1713.85% |
| 2024-03-31 | 1957.43% |
| 2023-12-31 | 1513.20% |
| 2022-06-30 | 155.07% |
| 2022-03-31 | 177.35% |
| 2021-12-31 | 97.58% |
| 2021-09-30 | 36.46% |
| 2021-06-30 | 29.20% |
| 2020-12-31 | 19.72% |
